Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 7/20 | 0.48 |
| ▸ | HTR1A | P08908 | 3/20 | 0.47 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | IDO1 | P14902 | 1/20 | 0.43 |
| ▸ | TDO2 | P48775 | 1/20 | 0.43 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.41 |
| ▸ | FEN1 | P39748 | 1/20 | 0.41 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6416990 | 0.85 | IDO1 (0.43) | GPR119HTR1ASLC6A4CYP2D6KDM4E | |
| SCHEMBL5204514 | 0.83 | HTR1A (0.55) | HTR1ASLC6A4TGFBR1ALDH1A1 | |
| SCHEMBL6411744 | 0.82 | SLC2A1 (0.49) | GPR119HTR1ASLC6A4KDM4EPKM | |
| SCHEMBL6411383 | 0.81 | HTR1A (0.50) | GPR119HTR1ASLC6A4CYP2D6 | |
| SCHEMBL6412168 | 0.80 | HTR1A (0.51) | HTR1ASLC6A4CYP2D6 | |
| SCHEMBL15684511 | 0.79 | KDM4E (0.51) | GPR119KDM4EPKMIDO1TDO2 | |
| SCHEMBL6412842 | 0.79 | HTR1A (0.50) | HTR1ASLC6A4CYP2D6USP30 | |
| SCHEMBL6411103 | 0.79 | HTR1A (0.50) | HTR1ASLC6A4CYP2D6USP30 | |
| SCHEMBL6411678 | 0.78 | HTR1A (0.49) | HTR1ASLC6A4CYP2D6 | |
| SCHEMBL6412710 | 0.78 | HTR1A (0.50) | HTR1ASLC6A4TGFBR1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050065140-A1 | Serotonine reuptake inhibitor | SUMITOMO PHARMACEUTICALS COMPANY LIMITED (JP) | 2005-03-24 | — | — | US | disclosed |
| EP-1466901-A1 | SEROTONINE REUPTAKE INHIBITOR | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 2004-10-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050065140-A1 | Serotonine reuptake inhibitor | HTR1A, SLC6A4, SLC6A2 | GPR119 279/4885HTR1A 1/4885SLC6A4 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.